Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Chief Accounting Officer & VP | March 06, 2023 | March 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date March 06, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,440 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Sale · Disposed 1,871 · Balance 27,440 F1: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 6, 2023 18:55 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | SaleCommon Stock | 1,871 | $0.98 | $1,833.58 |
DisclosureSEC source: 0001209191-23-016507 · doc4.xml · nonDerivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,440 F1 · shares: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 18:32 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001209191-23-006398 · doc4.xml · derivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 17:37 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | Tax withholdingCommon Stock | 1,640 | $0.72 | $1,180.80 |
DisclosureSEC source: 0001209191-22-060218 · doc4.xml · nonDerivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,311 F1 · shares: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 17:58 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | Tax withholdingCommon Stock | 1,520 | $1.64 | $2,492.80 |
DisclosureSEC source: 0001209191-22-049221 · doc4.xml · nonDerivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,951 F1 · shares: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 17:03 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-22-040306 · doc4.xml · derivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 16:13 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Tax withholdingCommon Stock | 1,529 | $3.12 | $4,770.48 |
DisclosureSEC source: 0001209191-22-035020 · doc4.xml · nonDerivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,471 F1 · shares: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 17:58 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016443 · doc4.xml · nonDerivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant. Read SEC document |
| December 14, 2021 Filed Jan 5, 2022 16:39 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001209191-22-001731 · doc4.xml · derivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-13 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:21 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $46.10 | $0.00 |
DisclosureSEC source: 0001209191-21-009949 · doc4.xml · derivative · entry 1 Monohon Ted · CIK 0001606905 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the Option shall vest and become exercisable on each monthly anniversary of the vesting start date (and if there is no corresponding day, the last day of the month). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.